Evidence map›Paper›PMID 22031337›Full record

ArticleCytometry. Part B, Clinical cytometry2012

Combined normal donor and CLL: Single tube ZAP-70 analysis.

Heba A Degheidy, David J Venzon, Mohammed Z H Farooqui, Fatima Abbasi, Diane C Arthur, Wyndham H Wilson, Adrian Wiestner, M A Stetler-Stevenson, Gerald E Marti

Open access · bronzeAbstract read
In one paragraph

Article in Cytometry. Part B, Clinical cytometry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Heba A DegheidyCenter for Biologics Evaluation and Research, FDA, Bethesda, Maryland, USA.
David J Venzon
Mohammed Z H Farooqui
Fatima Abbasi
Diane C Arthur
Wyndham H Wilson
Adrian Wiestner
M A Stetler-Stevenson
Gerald E Marti
Center for Biologics Evaluation and Research · USNational Heart Lung and Blood Institute · USNational Institutes of Health · US

Funding

Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapyZIAHL002346 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI WIESTNER, ADRIAN U · 2009 to 2025
$29.8M
Office of Collaborative BiostatisticsZIDSC007202 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI CHOO-WOSOBA, HYOYOUNG · 2009 to 2025
$14.5M
Therapeutic Strategies and Molecular Correlates in Aggressive B-cell LymphomasZIASC006741 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WILSON, WYNDHAM H · 2009 to 2025
$10.4M
Targeted treatment of B-cell LymphomaZIABC011354 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, WYNDHAM H · 2010 to 2025
$4.6M
Phase III Study of R-CHOP v DA-EPOCH-R with microarrayZIABC010728 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, WYNDHAM H · 2009 to 2021
$1.4M
Phase III study of BCL-family inhibitors in lymphomaZIABC010716 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, WYNDHAM H · 2009 to 2013
$1.1M
Phase II study of flavopiridol in mantle cell lymphoma and DLBCLZIABC010715 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, WYNDHAM H · 2009 to 2013
$689k
Intramural NIH HHS ZIA HL002346
6 · The paper itself

Abstract

introductionZeta-chain-associated protein kinase 70 (ZAP-70) has been identified as an independent prognostic marker in chronic lymphocytic leukemia (CLL). Based on our previous studies, we have developed a combined one-tube technology with multiple internal controls to optimize ZAP-70 assessment.

methodsForty-eight untreated CLL cases were examined for ZAP-70 expression using a modified 7-color one-tube assay. Normal donor (ND) whole blood is stained with CD3 APC-Cy7 and CD19 APC. In a second tube, patient whole blood is stained with CD5 PE-Cy7, CD19 PerCP-Cy5.5, and CD20 eFluor450. After surface staining and fixation, these two tubes are combined. After saponin permeabilization, the cells were stained with two anti-ZAP-70 clones (1E7.2/AF488 and SBZAP/PE). The results obtained from this modified tube were compared with those obtained concurrently using the non-mixed single sample tubes. Five different methods of ZAP-70 expression analysis were evaluated: percentage positive cells using ND T-cells as a reference; the internal patient T-cell/clone ratio; ND T-cell/clone ratio; clone/ND B-cell ratio; and modified Z-index.

resultOverall, the combined patient and ND mix tube performed better than the non-mixed single sample tube. The strongest correlations between ZAP-70 expression and immunoglobulin heavy chain variable (IGHV) mutational status were seen with percentage positive ND T-cell, ND T-cell/clone ratio, and clone/ND B-cell ratio for both 1E7.2 and SBZAP clone (P < 0.0001).

conclusionThe modified one tube method combining the ND and patient sample provides highly reliable results that correlate with the IGHV mutational status. This method should be considered as part of the next step in standardization of the ZAP-70 assay in CLL.

Indexed as

AgedAged, 80 and overAntibodies, MonoclonalAntigens, CD19Antigens, CD20Biomarkers, TumorB-LymphocytesCD3 ComplexCD5 AntigensFemaleFlow CytometryHumansImmunoglobulin Heavy ChainsLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedAntibodies, MonoclonalAntigens, CD19Antigens, CD20Biomarkers, TumorCD3 ComplexCD5 AntigensImmunoglobulin Heavy ChainsZAP70 protein, humanZAP-70 Protein-Tyrosine Kinase

Identifiers

PMID22031337
PMCPMC3407416
OpenAlexW2088905033

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.